Latest news
6 ways Johnson & Johnson is using AI to help advance healthcare
Artificial intelligence is revolutionizing healthcare—from improving surgical training and procedures to equipping healthcare providers with insights and personalizing care for patients around the world. See how the company is harnessing its extraordinary power.
More from Johnson & Johnson
What you need to know about Johnson & Johnson’s 2024 third quarter earnings
Check out this infographic breakdown of the company’s third quarter performance, with highlights from its Innovative Medicine and MedTech businesses.
What is a rheumatic disease?
More than 200 conditions are classified as rheumatic diseases, including rheumatoid arthritis, lupus and Sjögren’s disease. They tend to affect the joints and connective tissues, causing pain and swelling and impacting quality of life. Here’s what a doctor wants you to know about the different types, symptoms and risk factors—and how Johnson & Johnson is innovating new treatments.
Meet the medical engineer behind the innovative heart pump that revolutionized cardiac health
Drawing on his fascination with airplane technology, Thorsten Siess, Ph.D., came up with an idea that became the Impella heart pump. Now, 25 years since it entered the market, this groundbreaking device has helped more than 330,000 patients recover from heart injuries.
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
What you need to know about Johnson & Johnson’s 2023 transparency report
The annual report has just been released—here are key takeaways that showcase the company’s commitment to creating a more sustainable, equitable and innovative healthcare system.
How Johnson & Johnson is fighting counterfeit medical products
Fake medication and compromised devices are part of a global market that poses a significant threat to the health of patients. Here’s how the company’s Global Brand Protection team helps keep people safe.
Photo courtesy of GBP LATAM team
Press releases
Johnson & Johnson MedTech Completes Pilot Phase Enrollment of OMNY-AF Trial Evaluating Large-Tip, Focal Pulsed Field Ablation OMNYPULSE™ Catheter
The OMNY-AF trial evaluates safety and efficacy of the investigational OMNYPULSE™ Platform, a novel catheter that combines a large ablation area with mapping capabilities
Shockwave Medical Completes Enrollment in All-Female Coronary IVL Study
The first prospective female-only study of coronary interventions in complex calcific disease, EMPOWER CAD aims to confirm benefits of Shockwave intravascular lithotripsy in women Co-Principal Investigator Margaret McEntegart, MD, completed enrollment during a live case at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C.
European Commission Approves Expanded Use of HIV-1 Therapy EDURANT® (rilpivirine) in Younger Pediatric Patients
Approval provides a new treatment option for some of the youngest people living with HIV-1 in the European Union
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease
A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn’s disease (CD), pending FDA approval
New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
First-of-its-kind Phase 3b study shows TREMFYA® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living with moderate to severe plaque psoriasis
